Salma Makhoul Ahwach, MD
Endocrinology, Diabetes & Metabolism · Elmira, NYNPI 1467683524
Payments from drug & device makers
Across 212 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$772
- Abbott$721
- Mannkind Corporation$353
- Lilly USA, LLC$292
- Dexcom, Inc.$288
- Boehringer Ingelheim$239
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,79598%
- Education$80%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $772 |
| Abbott | 28 | $721 |
| Mannkind Corporation | 18 | $353 |
| Lilly USA, LLC | 25 | $292 |
| Dexcom, Inc. | 6 | $288 |
| Boehringer Ingelheim | 13 | $239 |
| Sanofi-aventis U.S. LLC | 8 | $156 |
| Amgen | 9 | $154 |
| AstraZeneca | 10 | $143 |
| Insulet Corporation | 8 | $135 |
| Medtronic | 2 | $106 |
| Xeris Pharmaceuticals, Inc. | 5 | $94 |
| Radius Health, Inc. | 4 | $80 |
| Corcept Therapeutics | 4 | $73 |
| AbbVie | 4 | $57 |
| Tandem Diabetes Care, Inc. | 3 | $54 |
| IBSA Pharma Inc. | 2 | $33 |
| Companion Medical, Inc. | 2 | $31 |
| Merck | 2 | $29 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Antares Pharma, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
| Vivus LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,863 in reported general payments places this provider in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 369 | $334,137 |
| TrulicityDulaglutide | 241 | $271,527 |
| OzempicSemaglutide | 165 | $216,796 |
| Tresiba Flextouch U-200Insulin Degludec | 145 | $170,959 |
| MounjaroTirzepatide | 56 | $68,285 |
| FarxigaDapagliflozin Propanediol | 76 | $63,795 |
| RybelsusSemaglutide | 39 | $54,262 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $52,640 |
| JanuviaSitagliptin Phosphate | 64 | $52,470 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $34,382 |
| Novolog FlexpenInsulin Aspart | 139 | $32,062 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $31,808 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 184 | $27,602 |
| Humalog Kwikpen U-100Insulin Lispro | 78 | $25,324 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $23,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $239 | $347,963386 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $292 | $343,592312 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $772 | $274,836220 claims |
| AstraZenecaFarxiga | $143 | $63,79576 claims |
| MerckJanuvia | $29 | $52,47064 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $2,588338 claims |
| Sanofi-aventis U.S. LLCLantus | $156 | $1,81612 claims |
| AbbVieSynthroid | $57 | $1,38625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Elmira
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
- Michael ShanikSmithtown$1.7M
- Robert SilverBrooklyn$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.